AgriTech Startup Funding 2025-2026

What are all the funding deals in the AgriTech market from July 2025 to June 2026?

The table below lists every disclosed equity round raised by pure-play AgriTech companies between July 2025 and June 2026. We define the AgriTech market as technologies purpose-built to improve agricultural production and input performance up to the farm gate.

We include on-farm hardware, software, services, precision agriculture, automation, sensors, farm management, decision support, and agricultural input innovation across seeds, traits, crop protection, biologicals, fertilizers, animal health, and feed. For a wider view of the market, we cover it in our AgriTech market report.

How active has fundraising been in the AgriTech market?

As of June 2026, fundraising in the AgriTech market has been active but uneven. Over the past 12 months, pure-play AgriTech companies raised 38 disclosed equity rounds and $779.286M combined.

That equals 3.17 disclosed rounds per month on average. The median monthly deal count is 2.5, which shows that activity was steady but not evenly distributed.

March 2026 was the strongest month by both deal count and capital. It produced 10 deals and $276.6M, helped heavily by Halter’s $220M Series E.

The dollar pattern is much spikier than the deal-count pattern. Average capital raised per month was $64.941M, but the median was $45.7M, so a few large months lifted the average.

If you want to go deeper on the companies behind this activity, see our AgriTech market report covering funding trends.

How concentrated has fundraising been in the AgriTech market?

As of June 2026, fundraising in the AgriTech market is highly concentrated. Over the past 12 months, the top deal accounted for 28.2% of total disclosed capital, while the top 3 deals reached 49.3%.

The top 5 deals represented 60.2% of total capital. The top 10 deals represented 75.7%, which means most dollars came from a small set of companies.

This is important because the AgriTech market looks broader by deal count than by capital. There are 38 deals in the sample, but capital formation is still mostly a large-round story.

The most practical reading rule is simple. When a headline says AgriTech funding is rising, ask whether the change came from broad market depth or from one large round.

How much of the AgriTech funding signal is driven by outliers?

As of June 2026, a large part of the AgriTech funding signal is driven by outliers. Over the past 12 months, Halter’s $220M Series E and Ecorobotix’s $105M Series D+ alone represented 41.7% of total disclosed capital.

Only 4 deals in the dataset were $50M or larger. Those rounds were rare by count, but they changed the market’s capital picture.

The stress test is useful. Total disclosed capital was $779.286M, but capital excluding rounds above $50M was only $395.286M.

That means the AgriTech market should not be read as a uniform funding boom. It is better understood as a selective market where investors write very large checks only when deployment evidence is strong.

Is the AgriTech market broad with many targets, or narrow with few fundable companies?

As of June 2026, the AgriTech market is broad by company count but narrow by capital formation. Over the past 12 months, the dataset contains 38 deals across 38 unique companies, so no single company repeated in the final screened sample.

Category breadth is real. The dataset includes farm automation, agricultural biologicals, animal health technologies, farm sensing platforms, precision agriculture tools, and input innovation.

But the dollar base is much narrower. The top 10 deals absorbed 75.7% of disclosed capital, so most funded companies sit outside the main capital pool.

This means the AgriTech market has many investable experiments but fewer scale-ready targets. The distinction matters because deal count measures exploration, while capital concentration measures conviction.

Is AgriTech mostly an early-stage formation market or a late-stage scaling market?

As of June 2026, the AgriTech market is both an early-stage formation market and a late-stage capital market. Over the past 12 months, Seed and Series A rounds produced 26 deals, or 68.4% of the sample, but only 25.6% of disclosed capital.

Seed was the most common stage, with 15 deals and $69.826M raised. The median Seed round was $4M, which points to proof-of-field and productization rather than rapid global rollout.

Series A was also healthy, with 11 deals and $129.6M raised. That suggests investors still finance early institutional scale-up when technical proof is paired with a specific crop, animal, input, or farm workflow.

Late-stage and growth rounds changed the dollar picture. Series B, Series C, Series D+, and Growth Equity together represented $574.46M, or 73.7% of total capital, from only 11 deals.

We cover this stage split in more detail in our deeper analysis of the AgriTech market.

Which categories attract the most investor attention in AgriTech?

As of June 2026, Farm Automation Systems and Agricultural Biologicals attract the most investor attention by deal count in the AgriTech market. Over the past 12 months, Farm Automation Systems produced 14 deals, while Agricultural Biologicals produced 13.

Together, those two categories represented 71.0% of all disclosed deals. That makes them the two largest areas of visible company formation in the AgriTech market.

The reasons are different. Farm Automation Systems offer labor savings and input reduction through machines, while Agricultural Biologicals offer new crop-input pathways through microbes, traits, biological crop protection, and fertilizer innovation.

Animal Health Technologies had only 7 deals, but those deals mattered disproportionately. The category captured 43.6% of total capital, mostly because of larger livestock, feed, and methane-reduction rounds.

Which categories attract disproportionately large checks in the AgriTech market?

As of June 2026, Animal Health Technologies attracted the most disproportionately large checks in the AgriTech market. Over the past 12 months, the category represented 18.4% of deals but 43.6% of total capital.

That gives Animal Health Technologies a capital-share-to-deal-share ratio of 2.37. This is the strongest ratio in the dataset and shows that investors wrote much larger checks in livestock and feed-related technologies.

Farm Sensing Platforms also punched above their deal count, with 5.3% of deals and 7.6% of capital. The category’s average deal size was $29.5M, helped by BinSentry’s $50M Series C.

Agricultural Biologicals showed the opposite pattern. The category had 34.2% of deals but only 12.6% of capital, which suggests broad experimentation but limited late-stage scale during the period.

Which geographies matter most for fundraising in the AgriTech market?

As of June 2026, Asia-Pacific, Europe, and North America matter most for AgriTech fundraising. Over the past 12 months, those three regions represented 94.1% of disclosed capital and 92.0% of disclosed deals.

Asia-Pacific led by capital, with $308.026M raised, or 39.5% of the total. That leadership was heavily influenced by Halter’s $220M round.

Europe led by deal count, with 14 deals, or 36.8% of all disclosed rounds. This makes Europe the densest experimentation region in the dataset.

North America had fewer deals than Europe but larger typical rounds. Its median deal size was $15M, compared with Europe’s $7.55M.

For more context on where the strongest regional opportunities are emerging, see our market report on AgriTech geographies.

Is the AgriTech opportunity set broad or concentrated in one hub?

As of June 2026, the AgriTech opportunity set is not concentrated in one hub. Over the past 12 months, Europe, Asia-Pacific, and North America all produced meaningful disclosed funding activity.

Europe led deal count with 14 rounds. Asia-Pacific followed with 11, and North America followed with 10.

The capital ranking looks different. Asia-Pacific led with 39.5% of capital, Europe captured 34.3%, and North America captured 21.7%.

Middle East and Latin America were visible but small in this screened dataset. Africa had no qualifying pure-player disclosed equity rounds, which likely reflects disclosure and financing-structure gaps as much as innovation gaps.

Is AgriTech a market of small experiments or scaled financings?

As of June 2026, the AgriTech market is mostly a market of small and mid-sized experiments, with a few scaled financings setting the headline. Over the past 12 months, the median disclosed round was $8.35M.

The size distribution supports that reading. There were 12 deals below $5M, 16 deals between $5M and $20M, 6 deals between $20M and $50M, and only 4 deals at $50M or above.

So most AgriTech rounds were not megarounds. The market’s visible activity sits mainly in the sub-$20M range, where companies can fund validation, early commercialization, or product expansion.

But the average round size was $20.51M, more than double the median. That gap shows how a few large rounds make the market look more scaled than the typical deal really is.

If you want the full breakdown of round sizes and funding patterns, explore our full AgriTech market deck.

Who are the investors that appear the most in AgriTech fundraising?

As of June 2026, the clearest repeat investor in the AgriTech market is Corteva or Corteva Catalyst. Over the past 12 months, it appeared in 4 qualifying deals: Ascribe Bio, IBI Ag, Resurrect Bio, and Puna Bio.

AgFunder also appears repeatedly, across Puna Bio, Singrow, and Resurrect Bio. That gives it 3 qualifying appearances in the screened dataset.

The Gates Foundation appears in 2 qualifying deals, Puna Bio and PlasmaLeap. Future Food Fund also appears in 2, Agreenculture and Mycoverse.

The investor pattern matters because technical AgriTech often needs more than capital. Strategic investors can help with validation, distribution, regulation, manufacturing, and farmer access.

One caveat is important. Investor counts here are based only on investors explicitly named in the cited announcement sources, and they do not estimate how much each investor personally committed.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.